30 results about "Malignant cells" patented technology

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

A pathological diagnosis support device comprises: an acquisition unit that acquires pathological images including cells as subjects; a determination unit that determines whether malignant cells are included in the pathological images by inputting the pathological images to a machine-trained first classification model; a classification unit that classifies the pathological images by class by inputting the pathological images to a second classification model machine-trained to classify the pathological image into any of a plurality of classes including one or more features suggesting the presence of malignant cells; and an output unit that outputs a classification result and supports a user's decision making.

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

The present invention provides an in-vitro method of reducing the efficiency of transducing malignant cells of the blood system of a subject that are not derived from T cells with lentiviral vector particles without reducing the efficiency of transducing T cells in a sample comprising T cells and said malignant cells. A combination of compositions comprising a first composition and a second composition is also disclosed, wherein said first composition comprises i) transduced T cells of a subject, wherein said transduced T cells express a CAR comprising an antigen binding domain, wherein the antigen binding domain of said CAR binds specifically to a tag of a tagged polypeptide, and ii) non-transduced malignant cells of the blood system of said subject, and wherein said second composition comprises said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of said malignant cells. Alternatively, the transduced T cells of said first composition may comprise a nucleic acid encoding a CAR and an inducible gene expression system, and said second composition may comprise an induction agent inducing said gene system.

Compounds and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part, thereby inhibiting the metastatic and invasive growth of malignant cells in a cancer patient.

The present disclosure relates to polynucleotides and methods of inhibiting the activities of development-associated pathways, including the Wnt, Hedgehog, and Notch pathways, and the invasive capacity of malignant cells to treat primary or secondary solid tumors.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

Embodiments of the present application disclose a pan-cancer cell recognition model training method, device, equipment and storage medium. The method comprises selecting transcriptome test data of a plurality of preset cancer types according to a preset ratio of normal cells and malignant cells to construct an initial data set; obtaining a preset number of high variable genes in the transcriptome test data of the initial data set as training features to obtain a training set; based on a binary classification label, performing label annotation on the transcriptome test data in the training set to generate a binary classification label system test data set; taking the pre-training weight of a preset base model as an initialization parameter, mounting a binary classification head at the top layer of a transformer layer, and performing parameter fine-tuning on the preset base model based on the binary classification label system test data set to obtain a pan-cancer cell recognition model. The scheme of the embodiments of the present application can realize accurate identification of benign and malignant cells in pan-cancer single-cell transcriptome data.

The present application is related to a method for in situ detection of multiple lung cancer-related markers in live circulating malignant cells, and tumor heterogeneity, including accurately detecting at least one lung cancer-related nucleic acid marker in live lung cancer cells by using a lung cancer-targeted nanoprobe loaded with a plurality of molecular beacons to reflect levels of different markers in the lung cancer cells from a single cell level and a heterogeneous state of a tumor of a specific patient. The nanoprobe is a nanoparticle self-assembled from a high polymer material, an electropositive protein, a functional polypeptide and / or a functional aptamer, and a molecular beacon of a lung cancer-related marker. The nanoprobe can be used to target different phenotype circulating malignant cells in whole blood, detect nucleic acid markers in living cells, and reflect levels of different markers in the malignant cells from a single cell level.

The invention relates to the technical field of biology, and discloses a method for discovering a new stomach-tumor target spot and a system establishment method. By integrating single cell second-generation sequencing and third-generation full-length transcriptome technologies and adopting a CopyKat and Infercnv dual algorithm model, the technical limitations that tumor heterogeneity cannot be analyzed by traditional batch sequencing and full-length new transcripts and malignant cells are difficult to accurately identify by conventional single cell sequencing are overcome. The method can systematically and precisely complete the whole process from cell subset analysis, malignant cell identification to brand new membrane protein target discovery, and further improves the reliability and transformation application potential of the discovered target through cross-platform verification and function correlation analysis, and has a wide application prospect. And a more efficient and reliable target spot discovery scheme is provided for gastric cancer targeted therapy and prognosis judgment.

The invention relates to the field of the preparation, identification and selection of biological binding molecules such as antibodies or fragments thereof, and also the use thereof in the context of therapy and prophylaxis of cancers, such as malignant B-cell neoplasia in particular. The binding molecules are capable of selectively binding to B-cell receptors that have a light chain according to SEQ ID NO. 18.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patient's antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

A classification assistance device comprises: a division unit that divides an input image, which includes a specimen being a subject that includes a plurality of cells, into a plurality of partial images, each including a plurality of cells as a subject; a patch classification unit that receives input of an image including a plurality of cells as a subject, inputs the partial images to a trained model trained to estimate whether the image includes malignant cells, and classifies whether a partial image includes malignant cells, on the basis of the estimation result of the trained model; a detection unit that detects cells from a partial image, among the plurality of partial images obtained by division by the division unit, that is classified by the patch classification means as including malignant cells; and a cell classification unit that classifies whether the cells detected by the detection unit are malignant cells. According to this classification assistance device, a user, such as a medical worker, can be assisted in making decisions.

This invention provides an antitumor agent that demonstrates efficacy against cancer cells expressing CD123, which has been reported to be overexpressed in malignant cells of a wide range of hematological malignancies. [Solution] Provided are an antibody or its antigen-binding fragment, an immune complex containing the antibody, and a method for using such CD123-binding molecules to diagnose and treat diseases such as B-cell malignancies, (a) an epitope within amino acids 101-346 of the human CD123 / IL3-Rα antigen, and (b) an antibody or its antigen-binding fragment that inhibits IL3-dependent proliferation of antigen-positive TF-1 cells.

The invention relates to the technical field of cellular immunotherapy, in particular to a preparation method of universal CAR-T (Chimeric Antigen Receptor-T) cells for targeting CD19 mediated by umbilical cord blood, and provides a standardized and large-scale preparation scheme aiming at the problems of long preparation period, high cost, large immune risk, limited applicable population and the like of the existing autologous CAR-T cells. The method comprises the steps of umbilical cord blood collection and storage, T cell separation and purification, CD19-targeted CAR gene construction and lentivirus transduction, TCR and HLA-I type molecule knockout through gene editing, CAR-T cell amplification and quality control and the like. The advantages of low immunogenicity and high multiplication capacity of the umbilical cord blood T cells are utilized, an optimized gene modification and culture system is combined, batch production of the CAR-T cells is achieved, the preparation period is shortened, the cost is reduced, adverse reactions such as GVHD and CRS are reduced, the applicable crowd for treatment is expanded, and an efficient and safe new strategy is provided for treatment of malignant B cell diseases.

The disclosure relates to a method for detecting the presence of at least one data point representative of malignant cell proliferation within a histopathological image, said method being implemented within an electronic processing device.Such a process comprises: - a segmentation (S01) of the representative image of the tissue section, yielding a set of tiles of predetermined size, each tile having a position within the representative image of the tissue section; - a determination (S02), for each tile in the set of tiles, of a data point representing the number of malignant cells and a data point representing the total number of cells, these data points being inserted respectively into a first matrix Mp and a second matrix Mt, each element of which is associated with a tile position within the representative image of the tissue section; - a detection (S03) of the presence of malignant cell proliferation within said histopathological image, said detection implementing calculations of data groupings from the first matrix Mp and the second matrix Mt, according to an algorithm for distributing calculations in parallel. Fig. 1.

Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and / or hyperplastic cells and / or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and / or hyperplastic cell growth and / or molecular imaging of malignant cells and / or hyperplastic cells and / or inducing degradation of a target protein. Also provided are compositions.

The present invention provides compositions and methods that can be used in methods for treating B-cell malignancies, and which exhibit low toxicity and immunogenicity in humans. [Solution] A chimeric antigen receptor (CAR) for CD19, comprising a specific amino acid sequence, is provided. A method for destroying T cells and malignant B cells expressing the CAR is also provided.

The invention belongs to the field of tumors, and relates to an application of NRF2 in regulation and control of arsenic-induced cell malignant proliferation, and the NRF2 gene of malignant proliferative cells is instantaneously knocked down. After the NRF2 is instantaneously knocked down, the G6PD / NADK mediated NADP synthesis increase is inhibited, so that the cell malignant proliferation phenotype caused by the cell redox steady state imbalance is reversed.

The present invention relates to a linking structure for linking an antibody to a drug toxic to malignant cells, and provides an antibody-drug conjugate represented by formula (I) obtained by linking an antibody to a cytotoxic drug via the linking structure. The definitions of each group in the formula are as described in the specification, and the antibody-drug conjugate has a significant antitumor effect. [Formula 1] JPEG2026501616000130.jpg23170

The invention discloses an antibody composition for screening CAR-T (Chimeric Antigen Receptor T) treatment AML (acute myeloid leukemia) target spots and application of the antibody composition. The antibody composition comprises a CD38 antibody, a CD371 antibody, a CD34 antibody, a CD117 antibody, a CD123 antibody, a CD33 antibody, a CD133 antibody and a CD45 antibody. When a sample to be detected is detected by adopting the antibody composition disclosed by the invention, malignant cell populations can be positioned and recognized more accurately, so that the antibody composition can be used for quickly and accurately screening CAR-T treatment AML (acute myeloid leukemia) targets, discovering signs of disease recurrence earlier and providing more information about disease prognosis; and doctors and patients are helped to better understand disease progresses and possible results.

The application provides a method for establishing a CRPC risk prediction model based on MaligC4 malignant cell phenotype characteristics, and relates to the technical field of CRPC risk prediction. The model is systematically verified in multiple independent cohorts (including TCGA, SU2C and multiple GEO data sets), so as to comprehensively evaluate its generalization ability. In addition, the application value of the probability score output by the model in clinical typing and prognosis stratification is explored. By integrating a robust feature construction strategy and a deep learning algorithm, a CRPC risk prediction framework with cross-cohort applicability and clinical transformation potential is constructed, which provides a new idea for accurately identifying high-risk patients and formulating individualized treatment strategies.

The application discloses a new actinium structure material obtained through first principle calculation and prediction, and belongs to the technical field of nuclear medical radiotherapy. The structure has an international symbol of Rm, a space group of 166, belongs to a trigonal system, a lattice constant of a=b=c=9.98371 Å, and a cell angle of α=β=γ=23.3174°. Ac1 is located at (0, 0, 0) in the cell, Ac2 is located at (0.77754, 0.77754, 0.77754), and Ac3 is located at (0.22246, 0.22246, 0.22246), thereby forming a layered hexagonal stacking structure. The structure has a low energy under normal pressure and is more stable than a traditional Fmm structure considered to be stable. Based on density functional theory calculation, the structure material has metallic properties, can be used for targeted alpha therapy, causes malignant cell death through alpha particle release, and has potential application value in the field of nuclear medical imaging and radiotherapy.

Disclosed are compositions and methods for targeted treatment of semaphorin 4A (SEMA4A)-expressing cancers. In particular, chimeric antigen receptors (CAR) are provided that are capable of targeting SEMA4A-expressing malignant cells. Also disclosed are isolated nucleic acid sequences encoding the disclosed CAR polypeptides, vectors comprising these isolated nucleic acids, and cells containing these vectors. Also disclosed is a method of providing an anti-tumor immunity in a subject with a SEMA4A-expressing cancer that involves administering to the subject an effective amount of an immune effector cell genetically modified with a disclosed SEMA4Aspecific CAR.

Disclosed are compositions and methods for targeted treatment of TRP1-expressing cancers. In particular, recombinant antibodies and chimeric antigen receptors capable of targeting TRP1-expressing malignant cells.

According to the gene set, the method, the product and the application for predicting the treatment response of the acute myelogenous leukemia, the prediction marker is screened from the key cell population of AML stem progenitor-like malignant cells, the core mechanism of disease recurrence and drug resistance is directly targeted, the biological significance is clear, and the application prospect is wide. Two brand-new gene sets related to AML treatment response and prognosis are found and verified, the limitation of dependence on known clinical and genetic factors in the prior art is broken through, prediction accuracy can be improved, precise medical requirements can be met, and by combining the discovery ability of single-cell transcriptome big data and verification convenience of batch transcriptome data, the prediction accuracy of AML treatment response and prognosis can be improved. An efficient technical path from basic research discovery to clinical verification is established, the developed prediction model has the dual functions of treatment response prediction and survival prognosis evaluation, the scheme is easy to standardize, and the clinical transformation potential is large.

The present disclosure generally relates to systems and methods of recirculating cells such as immune cells. In certain aspects, target cells attached to a chamber are provided, where cells such as immune cells can attach and be activated by the target cells. In some embodiments, flushing fluid through the chamber can remove non-attached cells. In certain aspects, activated cells can be used for determining information about the subject. For example, an aging-related response to a disease (e.g., cancer) can be determined from the activated cells. Other aspects include exposing cells such as immune cells to malignant cells such as cancer cells, kits or devices for conducting various methods described herein, or the like.

This disclosure provides bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and / or PD-L1.